Summary & Overview
HCPCS J1574: Ganciclovir Sodium (exela) Injection, 500 mg
HCPCS Level II code J1574 denotes a 500 mg injection of ganciclovir sodium (exela), billed when the specific product is not therapeutically equivalent to J1570. This code matters nationally because ganciclovir is an important antiviral used in the management of cytomegalovirus and other serious viral infections in immunocompromised patients; accurate coding affects drug utilization tracking, payer coverage determinations, and claims processing for high-cost parenteral therapies. Key payers considered in this analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find: benchmarks for how the code is reported relative to related antiviral injectables; the clinical context for use and typical sites of service such as outpatient infusion centers and hospital outpatient departments; common billing practices and coding distinctions tied to therapeutic equivalence notes; and a summary of policy considerations that influence payer coverage and reimbursement workflows. Data not available in the input will be noted where applicable, including associated taxonomies, ICD-10 diagnoses, and related codes.
Billing Code Overview
HCPCS Level II code J1574 represents an injection of ganciclovir sodium (exela), specified as not therapeutically equivalent to J1570, in a 500 mg dosage. This code is used to report administration of the specific branded or reseller-specified ganciclovir sodium product identified as exela.
Service Type: Drug administration — injectable antiviral agent
Typical Site of Service: Outpatient infusion center, hospital outpatient department, or physician office where parenteral antiviral therapy is administered
Clinical & Coding Specifications
Clinical Context
A 58-year-old immunocompromised patient with a history of solid-organ transplantation presents with fever, malaise, and new onset cytopenias. Laboratory testing and viral PCR confirm active cytomegalovirus (CMV) viremia. The treating infectious disease physician orders intravenous antiviral therapy with ganciclovir sodium prepared as a 500 mg injection billed with J1574. The patient receives the medication in an outpatient infusion center staffed by oncology/infectious disease nurses. The clinical workflow includes medication order entry, pharmacy compounding and verification of the specific ganciclovir product identified as not therapeutically equivalent to J1570, administration via peripheral IV or existing central venous access, nursing assessment during infusion, and documentation of dose, lot number, and any adverse reactions. Follow-up includes monitoring of CBC, renal function, and CMV viral load to guide duration and dosing adjustments.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
00 | Default/No modifier | Use when no specific modifier applies to the service |
22 | Increased procedural services | Use when unusually high complexity or additional time/resources were required for administration-related services